Project
Tapering from buprenorphine or methadone for pregnant women in opioid maintenance treatment (OMT) - project description
Published
Norwegian Institute of Public Health has been commissioned by the Norwegian Directorate of Health to carry out a systematic review of effects of methadone or buprenorphine tapering during pregnancy.
-
Project number
RL 023
-
Duration
6 mnd.
-
Start
04.2018
-
End
09.2018
-
Status
Concluded
-
Principal institution
-
Project owner/ Project manager
Folkehelseinstituttet -
Project description
-
Project manager
-
Participant at FHI
Intern fagfelle: Marte Handal (område for psykisk og fysisk helse, FHI)
-
External participants
Eksterne fagfeller oppnevnt av Helsedirektoratet: Gabrielle Welle-Strand (Helsedirektoratet), Fatemeh Chalabianloo (Haukeland universitetssjukehus), Yngvar Thorjussen (Borgestadklinikken)
Summary
Norwegian experts disagree in the question of whether women who become pregnant during opioid maintenance treatment (OMT), should have their OMT drug (methadone or buprenorphine) tapered, or whether they should continue maintenance treatment. We will systematically summarise research of effects for mother and child of tapering compared to continued maintenance treatment during pregnancy.